Objective. The objective of this study was to summarize the comparative efficacy and safety of MMF and AZA as maintenance therapy for LN.
Introduction
SLE is a complex autoimmune disease with multiorgan involvement. The course is usually characterized by remissions and relapses [1, 2] . LN is one of the most severe complications of this disease. It is estimated to affect up to 60% of adult patients with SLE [3] . Different types of LN ranging from mild mesangial proliferation to severe epithelial/endothelial proliferation progressing to glomerular sclerosis may ensue. Severe renal involvement in the absence of proper treatment leads to progressive deterioration of renal function and increased morbidity and mortality [4] . Therefore a main objective of the treatment of LES is the sustained control of LN to normalize renal function or to prevent the progressive loss of renal function.
Treatment of severe LN consists of an induction phase and a maintenance phase. Generally, high doses of corticosteroids and CYC are used as induction treatment of patients with International Society of Nephrology/Renal Pathology Society class III or IV disease. The new recommendations of the European League Against Rheumatism and European Renal AssociationEuropean Dialysis and Transplant Association (EULAR/ERA-EDTA) also consider the possibility of induction with MMF [5] . No significant difference in efficacy between CYC and MMF as induction therapy in LN was reported in meta-analyses [6, 7] . Because CYC therapy may cause a significant number of adverse events (AEs), including malignancy, the maintenance phase of the treatment consists of a combination of low doses of corticosteroids and MMF or AZA. However, the superiority of MMF vs AZA is disputed. One previous meta-analysis of MMF and AZA as maintenance therapy did not included all outcomes and the safety analysis was incomplete [8] . In the present review we summarize the efficacy and safety of MMF and AZA as maintenance therapy for LN, expanding the outcomes and the safety profile.
Materials and methods
A systematic literature review was performed to identify all publications that compared the efficacy and safety of MMF and AZA as maintenance treatment in LN. The protocol of the review is available by email upon request. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) consensus was followed for the review and meta-analysis [9] . 
Selection of articles
The selection criteria for articles were (i) inclusion of patients with LN, (ii) MMF and AZA were compared as maintenance treatment, (iii) efficacy and/or safety were available and (iv) the studies were intervention studies. Two reviewers (J.R.M. and N.L.C.) screened articles and abstracts for selection criteria independently, using a third reviewer (E.S.) for consensus. Once unrelated articles were excluded, the full report of all the selected studies was reviewed. Subsequently articles not fulfilling all selection criteria were excluded. In addition, a hand search of articles found in the reference lists of the included articles was made.
Data extraction
Data collected included publication details, study design, characteristics of patients, treatment results, definition of response and safety results. The definition of variables of response is in supplementary Table S1 , available at Rheumatology Online.
Risk of bias
The quality of studies was analysed using the Jadad scale [10] . The level of evidence was analysed according to Levels of Evidence of the Oxford Centre for Evidence Based Medicine.
Statistical analysis
Meta-analyses were performed using the random-effects approach with the DerSimonian and Laird method for computing summary relative risks (RRs) [11] . Metaanalysis was only planned if at least three studies or subanalyses with similar designs were available. For each available analysis, the effect was plotted by the inverse of its standard error to identify the risk of publication bias, assessing visually the symmetry of funnel plots, and its statistical significance using the Egger test [12] . Heterogeneity was tested as proposed by Higgins and Thompson using I 2 [13, 14] . An I 2 value >40% was arbitrarily chosen as a high level of heterogeneity. If high statistical heterogeneity was present, possible explanations were investigated using sensitivity analysis and metaregression. In the safety analysis, AEs were expressed using the incidence rate (IR). Differences in the more frequent AEs between MMF and AZA were calculated using crude and combined IR ratios (IRR) by the MantelHaenszel method. A P-value <0.10 was considered significant in the meta-regression and P < 0.05 was considered significant in other analyses. Stata software (Stata/IC 11.1 for Windows, StataCorp, College Station, TX, USA) was used in all statistical analysis.
Results
The search captured 7341 references. After title and abstract screening, 41 articles were retrieved for full-text review. A total of 36 articles were excluded after detailed review (supplementary Fig. S1 and Three studies analysed sustained remission as outcome and no significant differences were observed between MMF and AZA [16, 18, 19] . The meta-analysis showed an RR of 1.01 (95% CI 0.89, 1.14) and an I 2 of 0% (Fig. 1) showed an RR of 0.96 (95% CI 0.28, 3.25) with an I 2 of 5.8%. The Egger test was not significant (P = 0.939). Three studies reported data on discontinuation of treatment for AEs [16, 18, 19] . One showed a significantly lower rate of suspension in the MMF group [18] . The meta-analysis showed an RR of 0.60 (95% CI 0.41, 0.88) with an I 2 of 0% (Fig. 1) . The Egger test was significant (P = 0.012).
The results of the crude and combined IRR of AEs are shown in supplementary Table S4 available at Rheumatology Online. Gastrointestinal manifestations (including nausea, vomiting and diarrhoea) were more frequent in the MMF than AZA group, with a combined IRR of 1.68 (95% CI 1.06, 2.06). Leucopoenia was less frequent in the MMF group, with a combined IRR of 0.14 (95% CI 0.05, 0.42). No differences were found for other AEs such as infections, serious infections, herpes zoster or pneumonia. Three tumours were reported in the five studies included in the review. Two were cervical carcinoma [19] and the other an in situ uterine carcinoma [18] . All tumours occurred in the AZA group. This IRR could not be calculated for AEs due to the absence of events in the MMF group.
Discussion
In the present study we summarize the comparative data about the efficacy and safety of MMF and AZA as maintenance therapy for LN. These data are limited, but suggest no significant differences in the efficacy and safety of these drugs.
Our study has several limitations. First, the meta-analysis aggregated results from clinical trials with high heterogeneity in design, drug doses and treatment of the induction phase. Also, the quality of studies was low. Only one randomized, double-blind trial compared the efficacy and safety of MMF and AZA [18] . Another important limitation was the heterogeneity in variable definitions. Our study has several strengths, including consistency and the absence of significant heterogeneity in the results and no significant risks of publication bias in the included articles.
A meta-analysis of safety was not done because of the low frequency of some events and the expression of events as IR per 100 patients-years. However, to analyse differences in safety the IRRs of the most frequent AEs were calculated for MMF compared with AZA.
MMF is used as an immunosuppressant in transplant medicine. It seems superior to AZA at preventing graft rejection. However, in our analysis, no significant differences were found in efficacy. Nevertheless, a metaanalysis of relapse as a surrogate for lack of efficacy suggests a lower risk for MMF. The one randomized, double-blind trial showed relapse with MMF was less frequent than with AZA [18] .
Meta-analysis of mortality showed no differences between the MMF and AZA groups. Interestingly, discontinuation due to AEs was significantly lower with MMF than with AZA. The majority of patients treated with MMF as maintenance therapy were treated with MMF as induction therapy. Patients at risk of discontinuing because of AEs or inefficacy were probably excluded in the induction phase, hence their number in the maintenance phase was lower.
Results of subanalyses suggest a difference in response to the different regimens of induction and different populations. In patients with low estimated GFR, MMF may be faster in recovering kidney function compared with CYC [20] . Also, MMF may present advantages in response in Black and Hispanic patients [21] . However, these data could not be proved in the meta-analysis due to the small number of observations.
Although the safety profile of MMF and AZA was not significantly different, there were some variations. As expected, gastrointestinal AEs were more common with MMF and leucopoenia was more common with AZA. This is not surprising because these are common AEs of these drugs [2225] . Three malignancies were reported: two cervical carcinomas and one uterine carcinoma in situ in the AZA group. A relationship to previous use of CYC cannot be excluded [26] .
In conclusion, no significant differences in efficacy and safety were seen between MMF and AZA as maintenance treatment of LN. Nevertheless, the high heterogeneity of the studies included in the analysis make this contention questionable.
Rheumatology key messages
. Data of comparative efficacy and safety of MMF and AZA in maintenance treatment of LN is limited. . No significant differences in efficacy and safety appear between MMF and AZA in LN.
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